Literature DB >> 10588545

Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice.

K Ogawa1, M St John, M Luiza de Oliveira, L Arnold, T Shirai, T T Sun, S M Cohen.   

Abstract

The expression of uroplakins, the tissue-specific and differentiation-dependent membrane proteins of the urothelium, was analyzed immunohistochemically in N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-treated rats and mice during bladder carcinogenesis. Male Fischer 344 rats were treated with 0.05% BBN in the drinking water for 10 wk and were euthanatized at week 20 of the experiment. BBN was administered to male B6D2F, mice; it was either provided at a rate of 0.05% in the drinking water (for 26 wk) or 5 mg BBN was administered by intragastric gavage twice weekly for 10 wk, followed by 20 wk without treatment. In rats, BBN-induced, noninvasive, low-grade, papillary, transitional cell carcinoma (TCC) showed decreased uroplakin-staining of cells lining the lumen but showed increased expression in some nonluminal cells. In mice, nonpapillary, high-grade dysplasia, carcinoma in situ, and invasive carcinoma were induced. There was a marked decrease in the number of uroplakin-positive cells lining the lumen and in nonluminal cells. This occurred in normal-appearing urothelium in BBN-treated mice and in dysplasic urothelium, in carcinoma in situ, and in invasive TCC. The percentage of uroplakin-positive nonluminal cells was higher in control mice than in rats, but it was lower in the mouse than in the rat after BBN treatment. Uroplakin expression was disorderly and focal in BBN-treated urothelium in both species. These results indicate that BBN treatment changed the expression of uroplakins during bladder carcinogenesis, with differences in rats and mice being related to degree of tumor differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588545     DOI: 10.1177/019262339902700606

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  13 in total

1.  Expression and localization of four uroplakins in urothelial preneoplastic lesions.

Authors:  Daša Zupančič; Maja Zakrajšek; Ge Zhou; Rok Romih
Journal:  Histochem Cell Biol       Date:  2011-08-19       Impact factor: 4.304

2.  Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer.

Authors:  Nadine T Gaisa; Till Braunschweig; Nina Reimer; Jörg Bornemann; Elke Eltze; Sabine Siegert; Marieta Toma; Luigi Villa; Arndt Hartmann; Ruth Knuechel
Journal:  Virchows Arch       Date:  2010-12-07       Impact factor: 4.064

3.  Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models.

Authors:  Daša Zupančič; Mateja Erdani Kreft; Rok Romih
Journal:  Protoplasma       Date:  2013-07-05       Impact factor: 3.356

4.  Altered expression of UPIa, UPIb, UPII, and UPIIIa during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats.

Authors:  Daša Zupančič; Zdenka Ovčak; Gaj Vidmar; Rok Romih
Journal:  Virchows Arch       Date:  2011-02-08       Impact factor: 4.064

5.  Bladder cancers arise from distinct urothelial sub-populations.

Authors:  Jason Van Batavia; Tammer Yamany; Andrei Molotkov; Hanbin Dan; Mahesh Mansukhani; Ekaterina Batourina; Kerry Schneider; Daniel Oyon; Mark Dunlop; Xue-Ru Wu; Carlos Cordon-Cardo; Cathy Mendelsohn
Journal:  Nat Cell Biol       Date:  2014-09-14       Impact factor: 28.824

6.  Urothelial carcinogen resistance driven by stronger Toll-like receptor 2 (TLR2) and Uroplakin III (UP III) defense mechanisms: a new model.

Authors:  Leonardo Oliveira Reis; Karen Ferrari; Marina Zamuner; Guilherme Zweig Rocha; Athanase Billis; Wagner José Fávaro
Journal:  World J Urol       Date:  2014-05-29       Impact factor: 4.226

Review 7.  Animal models and therapeutic molecular targets of cancer: utility and limitations.

Authors:  Maria Cekanova; Kusum Rathore
Journal:  Drug Des Devel Ther       Date:  2014-10-14       Impact factor: 4.162

8.  ATG7 Overexpression Is Crucial for Tumorigenic Growth of Bladder Cancer In Vitro and In Vivo by Targeting the ETS2/miRNA196b/FOXO1/p27 Axis.

Authors:  Junlan Zhu; Yang Li; Zhongxian Tian; Xiaohui Hua; Jiayan Gu; Jingxia Li; Claire Liu; Honglei Jin; Yulei Wang; Guosong Jiang; Haishan Huang; Chuanshu Huang
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-14

9.  High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma.

Authors:  Susumu Kageyama; Tatsuhiro Yoshiki; Takahiro Isono; Tsutomu Tanaka; Chol Jang Kim; Takeshi Yuasa; Yusaku Okada
Journal:  Jpn J Cancer Res       Date:  2002-05

10.  Heterogeneity of uroplakin localization in human normal urothelium, papilloma and papillary carcinoma.

Authors:  Dasa Zupancic; Rok Romih
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.